214 related articles for article (PubMed ID: 32448830)
1. Secondary Pulmonary Alveolar Proteinosis Associated with Primary Myelofibrosis and Ruxolitinib Treatment: An Autopsy Case.
Sugiura H; Nishimori H; Nishii K; Toji T; Fujii K; Fujii N; Matsuoka KI; Nakata K; Kiura K; Maeda Y
Intern Med; 2020 Aug; 59(16):2023-2028. PubMed ID: 32448830
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis.
Chen YH; Lee CH; Pei SN
Leuk Lymphoma; 2015 May; 56(5):1528-9. PubMed ID: 25213182
[No Abstract] [Full Text] [Related]
3. Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis.
Miyawaki H; Kioka H; Sato K; Kurashige M; Ozawa T; Shibayama H; Hikoso S; Morii E; Yamauchi-Takihara K; Sakata Y
Intern Med; 2020 Jan; 59(2):229-233. PubMed ID: 31534088
[TBL] [Abstract][Full Text] [Related]
4. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
5. Erythematous skin lesions with necrotic centers on lower extremities due to the use of ruxolitinib for primary myelofibrosis.
Dasanu CA
J Oncol Pharm Pract; 2019 Jun; 25(4):990-992. PubMed ID: 29651917
[TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib: the first agent approved for myelofibrosis.
Verstovsek S
Clin Adv Hematol Oncol; 2012 Feb; 10(2):111-3. PubMed ID: 22402352
[No Abstract] [Full Text] [Related]
7. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Al-Ali HK; Griesshammer M; Foltz L; Palumbo GA; Martino B; Palandri F; Liberati AM; le Coutre P; García-Hernández C; Zaritskey A; Tavares R; Gupta V; Raanani P; Giraldo P; Hänel M; Damiani D; Sacha T; Bouard C; Paley C; Tiwari R; Mannelli F; Vannucchi AM
Br J Haematol; 2020 Jun; 189(5):888-903. PubMed ID: 32017044
[TBL] [Abstract][Full Text] [Related]
8. Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation.
Beauverd Y; Samii K
Int J Hematol; 2014 Nov; 100(5):498-501. PubMed ID: 25034748
[TBL] [Abstract][Full Text] [Related]
9. Verruconis gallopava in a patient with myelofibrosis on ruxolitinib.
Hsu A; Ulici V
Blood; 2020 Apr; 135(14):1189. PubMed ID: 32243521
[No Abstract] [Full Text] [Related]
10. Myelofibrosis after essential thrombocythemia complicated by alveolar proteinosis.
Tsutsumi Y; Tanaka J; Saito S; Tanaka Y; Kawamura T; Obara S; Noto S; Shimoyama N; Asaka M; Imamura M; Masauzi N
Leuk Lymphoma; 2003 Jun; 44(6):1049-52. PubMed ID: 12854908
[TBL] [Abstract][Full Text] [Related]
11. Osteolytic Lesions in Primary Myelofibrosis and Effect of Ruxolitinib Therapy: Report of a Case and Literature Review.
Bucelli C; Cattaneo D; Valli VB; Levati GV; Lonati S; Gianelli U; Iurlo A
Chemotherapy; 2018; 63(6):340-344. PubMed ID: 30965327
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.
Ostojic A; Vrhovac R; Verstovsek S
Future Oncol; 2011 Sep; 7(9):1035-43. PubMed ID: 21919691
[TBL] [Abstract][Full Text] [Related]
13. Isolated Nodal TBC Reactivation in a Patient with Post-Thrombocythemia Myelofibrosis Treated with Ruxolitinib: Case Report and Review of the Literature.
Santoro M; Rotolo C; Accurso V; Morreale I; Mancuso S; Siragusa S
Chemotherapy; 2021; 66(3):87-91. PubMed ID: 33784668
[TBL] [Abstract][Full Text] [Related]
14. Iatrogenic Kaposi's sarcoma in a myelofibrosis patient treated with ruxolitinib: Case-report, literature review, and French pharmacovigilance data.
Moutel M; Noel V; Jary A; Le QH; Lier C; Viguier M; Lebbe C; Azzouz B; Bani-Sadr F
Am J Hematol; 2022 Jan; 97(1):E31-E34. PubMed ID: 34724250
[No Abstract] [Full Text] [Related]
15. Ruxolitinib - better prognostic impact in low-intermediate 1 risk score: evaluation of the 'rete ematologica pugliese' (REP) in primary and secondary myelofibrosis.
Mazza P; Specchia G; Di Renzo N; Cascavilla N; Tarantini G; Capalbo SF; Urbano T; Albano F; Giovannni R; Falcone AP; Santeramo MT; Spinosa G; Pisconti S
Leuk Lymphoma; 2017 Jan; 58(1):138-144. PubMed ID: 27263544
[TBL] [Abstract][Full Text] [Related]
16. Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.
Del Rosario M; Tsai H; Dasanu CA
J Oncol Pharm Pract; 2018 Apr; 24(3):226-228. PubMed ID: 28436280
[TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib for myelofibrosis--an update of its clinical effects.
Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
[TBL] [Abstract][Full Text] [Related]
18. Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis.
Koshiishi M; Sueki Y; Kawashima I; Nakajima K; Mitsumori T; Kirito K
Intern Med; 2017 Sep; 56(17):2335-2338. PubMed ID: 28794380
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary alveolar proteinosis in a marble worker.
Yildirim BB; Akgedik R; Akgedik S; Nazaroglu H
Int J Occup Med Environ Health; 2016; 29(5):871-6. PubMed ID: 27518894
[TBL] [Abstract][Full Text] [Related]
20. Lung squamous cell carcinoma in pulmonary alveolar proteinosis.
Liu H; Wang Y; He W; Xu Q
Ann Thorac Cardiovasc Surg; 2014; 20 Suppl():650-3. PubMed ID: 24200658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]